A Phase 3 Multi-center Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children (Age 2 to <12 Years) and Infants (Age 6 Months to <2 Years) With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms TRAPEDS 2
- Sponsors LEO Pharma
- 13 Jun 2024 Status changed from not yet recruiting to recruiting.
- 18 Mar 2024 New trial record